---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-014334"
form_type: "8-K/A"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T22:55:47.375624+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eton withdraws SEC waiver request for Increlex financials; expects filing in Q3 2025

## Summary
- Company had requested a waiver from filing historical audited financials and pro forma statements for Increlex.
- After discussions with SEC on unique accounting treatment, waiver request was withdrawn.
- Eton now expects to prepare and file the required financial statements in Q3 2025.
- Several factors could still delay the filing beyond Q3 2025.
- Acquisition of Increlex from Ipsen closed on December 19, 2024.

## SEC filing metadata
- accession: 0001437749-25-014334
- form_type: 8-K/A
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925014334/0001437749-25-014334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925014334/eton20250426_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-014334
- JSON: https://secwatch.observer/filing/0001437749-25-014334.json
- Plain text: https://secwatch.observer/filing/0001437749-25-014334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.